Medtronic (Minneapolis) reported the start of SYMPLICITY HTN-3, the U.S. trial of its Symplicity renal denervation system for treatment-resistant hypertension. The first patient in this landmark study was enrolled at the Prairie Heart Institute at St. John's Hospital (Springfield, Illinois). Read More
